Please use a PC Browser to access Register-Tadawul
Get It
Candel Therapeutics Reports Results From Phase 3 Clinical Trial Evaluating CAN-2409 Viral Immunotherapy In Localized Prostate Cancer Patients; Viral Immunotherapy Achieved Primary Endpoint
CANDEL THERAPEUTICS, INC. CADL | 5.74 5.67 | -0.52% -1.22% Pre |
